Trial Profile
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus-Calmette Guerin (BCG) Instillation Therapy on the Quality of Life in Non-muscle-invasive Bladder Cancer (NMIBC) Patients: Results of a Prospective, Randomised Phase II Trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2012
Price :
$35
*
At a glance
- Drugs BCG (Primary) ; BCG (Primary) ; Gemcitabine (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 27 Sep 2012 New source identified (ClinicalTrials.gov: US National Institutes of Health record NCT01697306) and integrated.
- 06 Mar 2012 New trial record
- 28 Feb 2012 Results presented at the 27th Congress of the European Association of Urology.